Literature DB >> 19237610

Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.

Alexandre Boyer1, Marilène Paquet, Marie-Noëlle Laguë, Louis Hermo, Derek Boerboom.   

Abstract

Synergistic effects of dysregulation of the WNT/CTNNB1 and phosphatidylinositol 3-kinase (PI3K)/AKT pathways are thought to be important for the development and progression of many forms of cancer, including the granulosa cell tumor of the ovary. Sustained WNT/CTNNB1 signaling in Sertoli cells causes testicular degeneration and the formation of foci of poorly differentiated stromal cells in the seminiferous tubules in mice. To test if concomitant dysregulation of the WNT/CTNNB1 and PI3K/AKT pathways could synergize to cause testicular cancer, Pten(tm1Hwu/tm1Hwu);Ctnnb1(tm1Mmt/+);Amhr2(tm3(cre)Bhr/+) mice that express a dominant, stable CTNNB1 mutant and lack the expression of phosphatase and tensin homolog (PTEN) in their Sertoli cells were generated. These mice developed aggressive testicular cancer with 100% penetrance by 5 weeks of age, and 44% of animals developed pulmonary metastases by 4 months, whereas Pten(tm1Hwu/tm1Hwu);Amhr2(tm3(cre)Bhr/+) controls were phenotypically normal. Surprisingly, the tumors could not be classified as Sertoli cell tumors, but rather bore histologic and ultrastructural characteristics of granulosa cell tumors of the testis (GCTT). Pten(tm1Hwu/tm1Hwu);Ctnnb1(tm1Mmt/+);Amhr2(tm3(cre)Bhr/+) testicular tumors did not express CYP17, CYP19, germ cell nuclear antigen, estrogen receptor 1 or progesterone receptor, but expressed the early granulosa cell markers WNT4 and FOXL2, confirming the diagnosis of GCTT. Immunohistochemical analyses of Pten(tm1Hwu/tm1Hwu);Ctnnb1(tm1Mmt/+);Amhr2(tm3(cre)Bhr/+) GCTT demonstrated a tumor marker profile similar to that reported in human GCTT. Immunoblotting analyses revealed high levels of phosphorylation of AKT and the PI3K/AKT signaling effector FOXO1A in Pten(tm1Hwu/tm1Hwu);Ctnnb1(tm1Mmt/+);Amhr2(tm3(cre)Bhr/+) GCTT, suggesting the involvement of FOXO1A in the mechanism of GCTT development. Together, these data provide the first insights into the molecular etiology of GCTT and the first animal model for the study of GCTT biology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237610      PMCID: PMC2675650          DOI: 10.1093/carcin/bgp051

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  49 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

2.  A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR.

Authors:  Shivapriya Ramaswamy; Noriaki Nakamura; Isabelle Sansal; Louise Bergeron; William R Sellers
Journal:  Cancer Cell       Date:  2002-07       Impact factor: 31.743

Review 3.  One tissue, two fates: molecular genetic events that underlie testis versus ovary development.

Authors:  Jennifer Brennan; Blanche Capel
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

4.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

5.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

6.  Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene.

Authors:  Margareta D Pisarska; Jeehyeon Bae; Cynthia Klein; Aaron J W Hsueh
Journal:  Endocrinology       Date:  2004-04-01       Impact factor: 4.736

7.  Structural and functional modifications of sertoli cells in the testis of adult follicle-stimulating hormone receptor knockout mice.

Authors:  Amit Grover; M Ram Sairam; Charles E Smith; Louis Hermo
Journal:  Biol Reprod       Date:  2004-03-03       Impact factor: 4.285

8.  Granulosa cell-specific inactivation of follistatin causes female fertility defects.

Authors:  Carolina J Jorgez; Michal Klysik; Soazik P Jamin; Richard R Behringer; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2003-12-30

9.  Requirement of Bmpr1a for Müllerian duct regression during male sexual development.

Authors:  Soazik P Jamin; Nelson A Arango; Yuji Mishina; Mark C Hanks; Richard R Behringer
Journal:  Nat Genet       Date:  2002-10-07       Impact factor: 38.330

10.  Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development.

Authors:  Manuela Uda; Chris Ottolenghi; Laura Crisponi; Jose Elias Garcia; Manila Deiana; Wendy Kimber; Antonino Forabosco; Antonio Cao; David Schlessinger; Giuseppe Pilia
Journal:  Hum Mol Genet       Date:  2004-03-31       Impact factor: 6.150

View more
  20 in total

1.  β-catenin stabilization in gonadotropes impairs FSH synthesis in male mice in vivo.

Authors:  Derek Boerboom; Vikas Kumar; Alexandre Boyer; Ying Wang; Romain Lambrot; Xiang Zhou; Charlène Rico; Ulrich Boehm; Marilène Paquet; Christophe Céleste; Sarah Kimmins; Daniel J Bernard
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

Review 2.  Minireview: animal models and mechanisms of ovarian cancer development.

Authors:  Lisa K Mullany; JoAnne S Richards
Journal:  Endocrinology       Date:  2012-03-06       Impact factor: 4.736

3.  Identifying functional cancer-specific miRNA-mRNA interactions in testicular germ cell tumor.

Authors:  Nafiseh Sedaghat; Mahmood Fathy; Mohammad Hossein Modarressi; Ali Shojaie
Journal:  J Theor Biol       Date:  2016-05-25       Impact factor: 2.691

4.  WNT4 is required for normal ovarian follicle development and female fertility.

Authors:  Alexandre Boyer; Evelyne Lapointe; Xiaofeng Zheng; Robert G Cowan; Huaiguang Li; Susan M Quirk; Francesco J DeMayo; JoAnne S Richards; Derek Boerboom
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

Review 5.  Consequences of RAS and MAPK activation in the ovary: the good, the bad and the ugly.

Authors:  Heng-Yu Fan; Zhilin Liu; Lisa K Mullany; JoAnne S Richards
Journal:  Mol Cell Endocrinol       Date:  2011-12-16       Impact factor: 4.102

6.  A novel mouse model of testicular granulosa cell tumors.

Authors:  Xin Fang; Nan Ni; Yang Gao; David F Vincent; Laurent Bartholin; Qinglei Li
Journal:  Mol Hum Reprod       Date:  2018-07-01       Impact factor: 4.025

7.  The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling.

Authors:  Pradeep S Tanwar; Arno E Commandeur; LiHua Zhang; Makoto M Taketo; Jose M Teixeira
Journal:  Carcinogenesis       Date:  2012-09-07       Impact factor: 4.944

Review 8.  Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

Authors:  Michael P O'Connell; Ashani T Weeraratna
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-25       Impact factor: 4.693

9.  WNT5a is required for normal ovarian follicle development and antagonizes gonadotropin responsiveness in granulosa cells by suppressing canonical WNT signaling.

Authors:  Atefeh Abedini; Gustavo Zamberlam; Evelyne Lapointe; Catherine Tourigny; Alexandre Boyer; Marilène Paquet; Kanako Hayashi; Hiroaki Honda; Akira Kikuchi; Christopher Price; Derek Boerboom
Journal:  FASEB J       Date:  2015-12-14       Impact factor: 5.191

10.  Aberrant Wnt/β-Catenin Signaling Pathway in Testis of Azoospermic Men​.

Authors:  Marefat Ghaffari Novin; Reza Mirfakhraie; Hamid Nazarian
Journal:  Adv Pharm Bull       Date:  2015-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.